A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

484

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: Epcoritamab
DRUG: Investigator's Choice Chemotherapy

Sponsor

Genmab

Collaborators

[object Object]